Grant Bogle
About Grant Bogle
Grant Bogle, 67, joined Nuvalent’s board in December 2024 and is nominated as a Class I director for a term expiring at the 2028 annual meeting. He is a commercialization-focused biopharma executive: President & CEO of Epizyme (Aug 2021–Aug 2022) and prior Epizyme director (Sep 2019–Aug 2022); SVP & Chief Commercial Officer at Tesaro (2015–2019); and SVP, Pharmaceutical & Biotech Solutions at McKesson Specialty Health/U.S. Oncology (2007–2015). He holds a BA in economics (Dartmouth), an MBA (Columbia), and was a 2020 Fellow in Harvard’s Advanced Leadership Initiative .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Epizyme, Inc. | President & CEO | Aug 2021–Aug 2022 | Led company to acquisition; board service Sep 2019–Aug 2022 |
| Tesaro | SVP & Chief Commercial Officer | 2015–2019 | Commercial leadership in oncology |
| McKesson Specialty Health (formerly U.S. Oncology) | SVP, Pharmaceutical & Biotech Solutions | 2007–2015 | Commercial distribution solutions |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Epizyme, Inc. | Director | Sep 2019–Aug 2022 | Not disclosed |
| Other public boards (current) | — | — | None disclosed |
Board Governance
- Class I director nominee alongside CEO James R. Porter, Ph.D., and Chair Anna Protopapas; election for three-year term to 2028 .
- Independence: Board determined all directors except Porter and Shair are independent under Nasdaq and SEC rules; Bogle is an independent director .
- Committee assignments: 2024 committees were Audit (Srivastava, Hack, Gilliland), Compensation (Conley, Protopapas, Wheeler), and Nominating & Corporate Governance (Meyers, Pearlberg, Protopapas); Bogle was not disclosed as a committee member (joined Dec 2024) .
- Board leadership and process: Independent Chair (Protopapas) separate from CEO; non-management directors meet in executive session regularly and independent directors alone at least annually; board met six times in 2024 with each director attending ≥75% of board/committee meetings; all directors attended the 2024 annual meeting .
Fixed Compensation
| Component | Detail | Source |
|---|---|---|
| Cash fees (2024) | $3,082 (prorated for Dec 2024 start) | |
| Annual board retainer (policy) | Members $42,000; non-executive Chair additional $31,000 | |
| Committee retainers (policy) | Audit: Member $10,000 / Chair $20,000; Compensation: Member $7,500 / Chair $15,000; Nominating: Member $5,000 / Chair $10,000 |
Performance Compensation
| Equity Award Type | Grant date | Quantity/Value | Vesting | Notes |
|---|---|---|---|---|
| Initial RSU (director) | Dec 5, 2024 | 3,200 RSUs; grant-date value per share $93.73 | Equal annual installments over 3 years (policy) | Director RSUs are time-based, not performance-based |
| Initial Option (director) | 2024 (initial award) | 4,851 options outstanding as of 12/31/2024 | Equal monthly installments over 3 years (policy) | Options granted under non-employee director policy |
| Initial Award structure (policy) | — | Target $600,000 total value; 50/50 Option/RSU; caps 14,850 options / 7,425 RSUs | As above | Time-based vesting only; no performance metrics |
| Annual Award (policy) | At each annual meeting | Target $400,000 total value; 50/50 Option/RSU; caps 9,900 options / 4,950 RSUs | Full vest at earlier of 1-year or next annual meeting | Time-based vesting |
No director performance-linked equity (e.g., PSUs) is disclosed; PSUs introduced in 2025 apply to executives, not directors .
Other Directorships & Interlocks
| Category | Disclosure | Source |
|---|---|---|
| Current public company directorships | None disclosed for Bogle beyond Epizyme (ended 2022) | |
| Interlocks/conflicts | Compensation committee interlocks: None; Bogle is not on the compensation committee |
Expertise & Qualifications
- Deep commercialization, sales, marketing, and distribution leadership in oncology across Epizyme, Tesaro, and McKesson/U.S. Oncology .
- Education: BA (Dartmouth), MBA (Columbia), 2020 Harvard Advanced Leadership Initiative Fellow .
Equity Ownership
| Holder | Beneficial Ownership (Class A) | % Outstanding | Outstanding Awards (as of 12/31/2024) |
|---|---|---|---|
| Grant Bogle | 674 shares | <1% | 3,200 RSUs; 4,851 options |
Governance Assessment
- Strengths: Independent director with differentiated commercial expertise in oncology launch/scale; majority-independent board, independent Chair, regular executive sessions; robust attendance in 2024; anti-hedging policy and clawback framework enhance governance quality .
- Alignment and incentives: Initial director equity is sizable (~$600k split 50/50) with multi-year vesting, supporting retention and alignment; cash retainer levels are standard for Nasdaq biopharma peers .
- Watch items: Low direct beneficial ownership (<1%) and newness to the board (joined Dec 2024) mean limited long-run ownership alignment data so far; no committee assignments disclosed yet, reducing immediate committee-level influence .
- Conflicts/related party exposure: No related-person transactions disclosed involving Bogle; board policies require audit committee review of related-party transactions; existing company agreements with Deerfield Funds and with director/scientific founder Matthew Shair are disclosed, but not linked to Bogle .
RED FLAGS: None identified specific to Bogle (no pledging/hedging, no related-party transactions, no committee interlocks). Monitoring warranted on future committee assignments and ownership accumulation to strengthen alignment .